Literature DB >> 18382213

Nonischemic heart failure in diabetes mellitus.

Ashrith Guha1, Romain Harmancey, Heinrich Taegtmeyer.   

Abstract

PURPOSE OF REVIEW: Diabetic patients with heart failure have a poor prognosis. Although it has been demonstrated in animal models that metabolic maladaptation plays a pivotal role in contractile dysfunction of the heart, the understanding of 'diabetic cardiomyopathy' and its treatment in humans remains incomplete. RECENT
FINDINGS: Epidemiological studies show that structural changes in the left ventricle can be demonstrated before onset of clinical diabetes. Diastolic dysfunction is the earliest manifestation that is associated with increasing level of serum-free fatty acids and worsening glycemic control. Spectroscopic and histologic evidence in the human myocardium indicates a maladaptive metabolic response in diabetes, characterized by intramyocellular triglyceride accumulation. Studies also suggest a link between myocardial isoform switching, calcium homeostasis and altered metabolism in the development of heart failure. However, treatment directed at deranged metabolic control in diabetes is effective only in animals, and not in humans.
SUMMARY: Although clinical studies suggest the existence of 'diabetic cardiomyopathy', it is still difficult to prove causality. However, animal models and human studies suggest that systemic metabolic derangements may lead to metabolic, functional and structural maladaptation of the heart. The exact mechanisms of heart failure in diabetes remain elusive.

Entities:  

Mesh:

Year:  2008        PMID: 18382213      PMCID: PMC3625426          DOI: 10.1097/HCO.0b013e3282fcc2fa

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  77 in total

1.  Relation of hemoglobin A1c to left ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart disease.

Authors:  Mehdi H Shishehbor; Byron J Hoogwerf; Paul Schoenhagen; Steven P Marso; Jing P Sun; Jianbo Li; Allan L Klein; James D Thomas; Mario J Garcia
Journal:  Am J Cardiol       Date:  2003-06-15       Impact factor: 2.778

Review 2.  Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome.

Authors:  Gianluca Iacobellis; Arya M Sharma
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

3.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

4.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

Authors:  M N Ghazzi; J E Perez; T K Antonucci; J H Driscoll; S M Huang; B W Faja; R W Whitcomb
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

5.  Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction.

Authors:  C Depre; M E Young; J Ying; H S Ahuja; Q Han; N Garza; P J Davies; H Taegtmeyer
Journal:  J Mol Cell Cardiol       Date:  2000-06       Impact factor: 5.000

6.  Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart.

Authors:  Norbert Fülöp; Meredith M Mason; Kaushik Dutta; Peipei Wang; Amy J Davidoff; Richard B Marchase; John C Chatham
Journal:  Am J Physiol Cell Physiol       Date:  2006-11-29       Impact factor: 4.249

Review 7.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.

Authors:  Dean T Eurich; Finlay A McAlister; David F Blackburn; Sumit R Majumdar; Ross T Tsuyuki; Janice Varney; Jeffrey A Johnson
Journal:  BMJ       Date:  2007-08-30

Review 8.  Diabetic cardiomyopathy revisited.

Authors:  Sihem Boudina; E Dale Abel
Journal:  Circulation       Date:  2007-06-26       Impact factor: 29.690

Review 9.  Hemodynamic actions of insulin.

Authors:  A D Baron
Journal:  Am J Physiol       Date:  1994-08

10.  Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes.

Authors:  Michaela Scheuermann-Freestone; Per L Madsen; David Manners; Andrew M Blamire; Robin E Buckingham; Peter Styles; George K Radda; Stefan Neubauer; Kieran Clarke
Journal:  Circulation       Date:  2003-06-16       Impact factor: 29.690

View more
  19 in total

1.  Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats.

Authors:  Sanda Despa; Kenneth B Margulies; Le Chen; Anne A Knowlton; Peter J Havel; Heinrich Taegtmeyer; Donald M Bers; Florin Despa
Journal:  Circ Res       Date:  2012-01-24       Impact factor: 17.367

2.  Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes.

Authors:  Sarah Brice Russo; Catalin F Baicu; An Van Laer; Tuoyu Geng; Harinath Kasiganesan; Michael R Zile; L Ashley Cowart
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

Review 3.  Cardiac anaplerosis in health and disease: food for thought.

Authors:  Christine Des Rosiers; François Labarthe; Steven G Lloyd; John C Chatham
Journal:  Cardiovasc Res       Date:  2011-03-11       Impact factor: 10.787

4.  Myristate-derived d16:0 sphingolipids constitute a cardiac sphingolipid pool with distinct synthetic routes and functional properties.

Authors:  Sarah Brice Russo; Rotem Tidhar; Anthony H Futerman; L Ashley Cowart
Journal:  J Biol Chem       Date:  2013-03-25       Impact factor: 5.157

5.  Insulin resistance: marker or mediator?

Authors:  Guha Ashrith; Mohammed F Algahim; Heinrich Taegtmeyer
Journal:  Am J Med       Date:  2009-03       Impact factor: 4.965

6.  Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study.

Authors:  Giovanni de Simone; Richard B Devereux; Marcello Chinali; Elisa T Lee; James M Galloway; Ana Barac; Julio A Panza; Barbara V Howard
Journal:  J Hypertens       Date:  2010-02       Impact factor: 4.844

7.  Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.

Authors:  Kathleen Guglielmino; Kaleena Jackson; Todd R Harris; Vincent Vu; Hua Dong; Gavin Dutrow; James E Evans; James Graham; Bethany P Cummings; Peter J Havel; Nipavan Chiamvimonvat; Sanda Despa; Bruce D Hammock; Florin Despa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-03       Impact factor: 4.733

Review 8.  Sphingolipids in obesity, type 2 diabetes, and metabolic disease.

Authors:  S B Russo; J S Ross; L A Cowart
Journal:  Handb Exp Pharmacol       Date:  2013

9.  Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview.

Authors:  Jessica S Ross; Sarah B Russo; Georgia C Chavis; Lauren A Cowart
Journal:  Clin Lipidol       Date:  2017-01-18

10.  Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study.

Authors:  Magnus T Jensen; Peter Sogaard; Ida Gustafsson; Jan Bech; Thomas F Hansen; Thomas Almdal; Simone Theilade; Tor Biering-Sørensen; Peter G Jørgensen; Søren Galatius; Henrik U Andersen; Peter Rossing
Journal:  Diabetologia       Date:  2019-10-30       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.